文献速递肝病消化道肿瘤与早癌

直接抗病毒药物治疗在美国退伍军人肝细胞癌患者中的有效性

Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
PubMed 文献 · J Hepatol · 2017-03-04

在2014年1月1日至2015年6月30日期间,美国退伍军人健康管理系统中17487例接受抗病毒治疗的丙肝患者中,624例(3.6%)有肝细胞癌病史。总体持续病毒学应答率在无肝癌患者中为91.1%,肝癌患者中为74.4%,肝癌肝移植后患者中为94.0%。调整混杂因素后,肝癌与较低的持续病毒学应答可能性相关(AOR 0.38 [95% CI 0.29, 0.48],p<0.001)。

要点

  • 肝癌患者直接抗病毒药物治疗的持续病毒学应答率为74.4%,肝移植后为94.0%
  • 基因1型肝癌患者持续病毒学应答率最高,基因3型最低
  • 调整混杂后肝癌与较低持续病毒学应答可能性独立相关(AOR 0.38)

核心结论

  • 大多数有肝癌病史的丙肝患者可通过直接抗病毒药物治愈,肝移植后肝癌患者几乎均可治愈。
  • 对于等待肝移植的肝癌患者,可考虑将丙肝治疗推迟至移植后。

研究设计与样本

  • 研究为在美国退伍军人健康管理系统中进行的队列研究,纳入2014年1月1日至2015年6月30日期间启动抗病毒治疗的17487例丙肝患者。
  • 治疗方案包括索非布韦、雷迪帕韦/索非布韦、帕利瑞韦/利托那韦/奥比他韦联合达萨布韦,联合或不联合利巴韦林。
  • 肝癌患者分为肝癌肝移植组(142例)和肝癌非肝移植组(482例)。

主要发现

  • 624例(3.6%)有肝癌病史,其中肝癌肝移植组142例,肝癌非肝移植组482例。
  • 总体持续病毒学应答率:无肝癌患者91.1%,肝癌患者74.4%,肝癌肝移植患者94.0%。
  • 肝癌患者中基因1型持续病毒学应答率最高(肝癌组79.1%,肝癌肝移植组96.4%),基因3型最低(肝癌组47.0%,肝癌肝移植组88.9%)。
  • 调整混杂因素后,肝癌与较低的持续病毒学应答可能性相关(AOR 0.38 [95% CI 0.29, 0.48],p<0.001)。

临床怎么用

  • 对于有肝癌病史的丙肝患者,直接抗病毒治疗可使多数患者获得病毒学治愈。
  • 对于等待肝移植的肝癌患者,可考虑将丙肝治疗推迟至移植后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Hepatitis C virus (HCV) treatment for patients with hepatocellular carcinoma (HCC) was uncommon before direct-acting antiviral (DAA) medications. Real-world effectiveness of DAAs for HCV in patients with HCC is unclear. We describe rates of sustained virologic response (SVR) with DAA regimens by HCV genotype in patients with a history of HCC. METHODS: We identified patients who initiated antiviral treatment between January 1, 2014 and June 30, 2015 in the national Veterans Affairs health care system. Regimens included sofosobuvir, ledipasvir/sofosbuvir, and paritaprevir/ritonavir/ombitasvir and dasabuvir with or without ribavirin. HCC patients were divided into those who were treated with liver transplantation after HCC diagnosis ("HCC/LT" group) and those treated with other modalities prior to antiviral therapy ("HCC" group). RESULTS: Of 17,487 HCV treatment recipients, 624 (3.6%) had prior HCC, including 142 with HCC/LT and 482 with HCC. Overall SVR was 91.1% in non-HCC, 74.4% in HCC, and 94.0% in HCC/LT. Among HCC patients, genotype 1 had the highest SVR overall (79.1% in HCC and 96.4% in HCC/LT), and genotype 3 the lowest (47.0% in HCC and 88.9% in HCC/LT). After adjustment for confounders, the presence of HCC was associated with lower likelihood of SVR overall (AOR 0.38 [95% CI 0.29, 0.48], p<0.001). CONCLUSION: HCV can be cured with DAAs in the majority of patients with prior HCC, and in virtually all HCC patients post-liver transplant. Deferral of HCV treatment until the post-transplant setting may be considered among HCC patients listed for transplantation. LAY SUMMARY: Over three-quarters of patients with hepatocellular carcinoma who have hepatitis C can achieve viral cure with direct-acting antiviral drugs. Among patients with hepatocellular carcinoma who subsequently received liver transplantation, over 90% of patients can achieve viral cure.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Beste LA, Green PK, Berry K, et al. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017. PMID: 28267622. doi:10.1016/j.jhep.2017.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。